ANTINEOPLASTIC ACTIVITY OF MITOXANTRONE AND ITS BIOLOGICAL INTERACTIONS IN PARENTAL AND MULTIDRUG RESISTANT SUBLINE OF P388 MURINE LEUKEMIA-CELLS

被引:0
|
作者
CHAVAN, S [1 ]
PAREKH, H [1 ]
CHITNIS, M [1 ]
机构
[1] UNIV MINNESOTA, SCH MED, DEPT PHARMACOL, MINNEAPOLIS, MN 55455 USA
关键词
MITOXANTRONE CYTOTOXICITY; BIOCHEMICAL DNA LESIONS; SENSITIVE AND MULTIDRUG RESISTANT P388 LEUKEMIA CELLS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The antitumor effects of mitoxantrone (MITO) and the various mechanisms involved therein were investigated in the adriamycin sensitive (P388/S) and resistant (P388/ADR) P388 leukemia cells utilizing the MTT (3-[4,5/dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay, MITO concentration < 100 ng elicited 50% inhibition of P388/S tumor cell survival, while a 10 times greater dose of MITO was required to inhibit the P388/ADR cell survival by 50%. A MITO dose dependent inhibition of DNA, RNA and protein biosynthesis was observed in the sensitive cells, while MITO elucidated a negligible effect on the macromolecular biosynthesis in the resistant tumor cells. Induction or DNA strand scission was observed in P388/S cells exposed to 0.1 and 1-mu-g/ml MITO, while a minimal formation of DNA lesions was evident in the P388/ADR cells treated with 5-mu-g/ml MITO. These strand breaks were found to be not associated with proteins in either P388/S or P388/ADR cells. Generation of free radicals due to MITO and formation of alkylating metabolites of MITO were found to be not involved in the cytotoxic response of MITO against P388/S and P388/ADR cells. MITO did not affect the glutathione based detoxification mechanism of the sensitive and resistant tumor cells. Results indicate that in spite of reduced intracellular drug retention and induction of DNA strand breaks in P388/ADR cells other hitherto unknown mechanisms besides DNA binding might be involved in the antitumorigenic potential of MITO.
引用
收藏
页码:49 / 57
页数:9
相关论文
共 50 条
  • [1] MECHANISM OF ACQUIRED-RESISTANCE TO METHOTREXATE IN P388 MURINE LEUKEMIA-CELLS AND IN THEIR DOXORUBICIN-RESISTANT SUBLINE
    RAMU, N
    RAMU, A
    COLE, DE
    BALIS, FM
    POPLACK, DG
    POLLARD, HB
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1988, 24 (9-10): : 477 - 482
  • [2] P388 LEUKEMIA-CELLS RESISTANT TO THE ANTHRACYCLINE MENOGARIL LACK MULTIDRUG RESISTANT PHENOTYPE
    BADINER, GJ
    MOY, BC
    SMITH, KS
    TARPLEY, WG
    GROPPI, VE
    BHUYAN, BK
    BRITISH JOURNAL OF CANCER, 1990, 62 (03) : 378 - 384
  • [3] CROSS-RESISTANCE OF MENOGARIL AND MITOXANTRONE IN A SUBLINE OF P388 LEUKEMIA RESISTANT TO DOXORUBICIN
    CHANDRASEKARAN, B
    DIMLING, J
    CAPIZZI, RL
    CANCER TREATMENT REPORTS, 1987, 71 (02): : 195 - 196
  • [4] RESTORATION OF DOXORUBICIN RESPONSIVENESS IN DOXORUBICIN-RESISTANT P388 MURINE LEUKEMIA-CELLS
    RAMU, A
    SPANIER, R
    RAHAMIMOFF, H
    FUKS, Z
    BRITISH JOURNAL OF CANCER, 1984, 50 (04) : 501 - 507
  • [5] CHARACTERIZATION OF A P388 LEUKEMIA SUBLINE SELECTED INVIVO FOR RESISTANCE TO MITOXANTRONE (MX)
    HARKER, WG
    SLADE, DL
    LEUKEMIA, 1987, 1 (03) : 277 - 277
  • [6] EVIDENCE FOR IMPAIRED MITOXANTRONE AND VINBLASTINE BINDING IN P388-MURINE LEUKEMIA-CELLS WITH MULTIDRUG RESISTANCE
    PINCUS, R
    GOLDMAN, ID
    BIOCHEMICAL PHARMACOLOGY, 1990, 40 (12) : 2625 - 2635
  • [7] INHIBITION OF DNA BIOSYNTHESIS BY VINCRISTINE AND PENTOXIFYLLINE IN MURINE P388 LEUKEMIA-CELLS RESISTANT TO DOXORUBICIN
    CHITNIS, MP
    VILADKAR, AB
    JUVEKAR, AS
    NEOPLASMA, 1990, 37 (06) : 619 - 626
  • [8] RESTORATION OF DRUG SENSITIVITY BY NITROXAZEPINE HYDROCHLORIDE IN P388 MURINE LEUKEMIA-CELLS RESISTANT TO ADRIAMYCIN
    CHITNIS, MP
    PRADHAN, SG
    SATYAMOORTHY, K
    BASRUR, VS
    CANCER DRUG DELIVERY, 1987, 4 (01): : 1 - 9
  • [9] RESTORATION OF DOXORUBICIN RESPONSIVENESS IN DOXORUBICIN-RESISTANT P388 MURINE LEUKEMIA-CELLS BY DIPYRONE
    CHITNIS, MP
    KAMATH, NS
    ONCOLOGY, 1987, 44 (01) : 47 - 50
  • [10] SENSITIZATION OF P388 MURINE LEUKEMIA-CELLS TO EPIRUBICIN CYTOTOXICITY BY RESERPINE
    VILADKAR, A
    CHITNIS, M
    CANCER BIOTHERAPY, 1993, 8 (01): : 77 - 85